Market Place
Sourcing Support
Innovent links cytokine fusion protein to responses in colorectal cancer
18 Sep 2024 //
FIERCE BIOTECH
Innovent Presents Data In Combination With Bevacizumab For Colorectal Cancer
17 Sep 2024 //
PR NEWSWIRE
Sutro Biopharma Announces Luvelta Combo Phase 1b Data At ESMO 2024
14 Sep 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Attends Chardan Virtual Ophthalmology Conference
13 Sep 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Completes NORSE EIGHT Trial Enrollment
04 Sep 2024 //
GLOBENEWSWIRE
Outlook Therapeutics to Present at H.C. Wainwright Global Conference
03 Sep 2024 //
GLOBENEWSWIRE
Pfizer`s Biologic Zirabev (Bevacizumab) Receives Suppl Approvals in US
28 Aug 2024 //
FDA
Outlook Therapeutics Reports Q3 FY 2024 Financial Results And Corporate Update
14 Aug 2024 //
GLOBENEWSWIRE
Sutro Biopharma Reports Q2 2024 Results And Anticipated Milestones
13 Aug 2024 //
GLOBENEWSWIRE
Outlook Therapeutics To Present At H.C. Wainwright Conference
12 Aug 2024 //
GLOBENEWSWIRE
Boundless Bio Reports Q2 2024 Results And Provides Business Updates
12 Aug 2024 //
GLOBENEWSWIRE
Outlook Therapeutics To Report Q3 FY 2024 Results On August 14
07 Aug 2024 //
GLOBENEWSWIRE
Outlook Therapeutics To Present At BTIG Virtual Biotechnology Conference
30 Jul 2024 //
GLOBENEWSWIRE
Junshi`s Toripalimab Combo NDA Accepted For Liver Cancer
17 Jul 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Announces UK MHRA Approval Of LYTENAVA™ For Wet AMD
08 Jul 2024 //
GLOBENEWSWIRE
Tempest Unveils New Data For Amezalpat Showing Six-Month Improvement
20 Jun 2024 //
GLOBENEWSWIRE
Junshi Biosciences Announces Ph3 Study of Toripalimab Combined with Bevacizumab
11 Jun 2024 //
GLOBENEWSWIRE
Bio-Thera`s Avastin Biosimilar Avzivi Gets Positive CHMP Opinion
03 Jun 2024 //
PR NEWSWIRE
Outlook Therapeutics: EU Approval For LYTENAVA Wet AMD Treatment
28 May 2024 //
GLOBENEWSWIRE
IMUNON`s IMNN-001 Plus Bevacizumab Phase 2 Study Abstract Accepted At ASCO
15 May 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Reports Q2 Fiscal 2024 Results, Corporate Update
15 May 2024 //
GLOBENEWSWIRE
MEI Pharma: ME-344 + Avastin® Data In Colorectal Cancer
11 Apr 2024 //
BUSINESSWIRE
Dr. Reddy`s Lab launches Versavo in the UK
20 Mar 2024 //
INDIANPHARMAPOST
Dr. Reddy`s Laboratories launches Versavo® (bevacizumab) in the UK
19 Mar 2024 //
PRESS RELEASE
Memorial Sloan Kettering Cancer Center Enrolling in Phase 1/2 Trial of IMNN-001
27 Feb 2024 //
GLOBENEWSWIRE
Biocon Biologics partners with Sandoz Australia for Biosimilars
10 Feb 2024 //
INDIAN PHARMA POST
FDA Approves Bio-Thera Solutions` Avzivi, a biosimilar referencing Avastin®
07 Dec 2023 //
PR NEWSWIRE
IMFINZI & bevacizumab met endpoint for progression-free survival in liver cancer
09 Nov 2023 //
BUSINESSWIRE
Outlook to conduct another trial for wet AMD drug; Cara strikes new royalty deal
03 Nov 2023 //
ENDPTS
Enforcement Report - Week of October 25, 2023
25 Oct 2023 //
FDA
IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001
18 Oct 2023 //
GLOBENEWSWIRE
Ascletis Announces Completion of Enrollment of Patients in PIII Trial of ASC40
25 Sep 2023 //
PR NEWSWIRE
Maintenance Mirvetuximab Soravtansine Plus Bevacizumab in FR?+ Ovarian Cancer
01 Sep 2023 //
ONCLIVE
Trifluridine/Tipiracil Plus Bevacizumab Provides Potential 1st-Line Alternative
30 Aug 2023 //
ONCLIVE
MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344
16 Aug 2023 //
BUSINESSWIRE
FDA approves Taiho`s Lonsurf with bevacizumab for metastatic colorectal cancer
03 Aug 2023 //
ENDPTS
FDA Approves LONSURF in Combination With Bevacizumab for mCRC
02 Aug 2023 //
PR NEWSWIRE
NOX-A12 Plus Bevacizumab & Radiotherapy Shows Sustained Survival in Glioblastoma
29 Jun 2023 //
ONCLIVE
Enzene Biosciences launches Bevacizumab
29 Jun 2023 //
#N/A
Tvardi doses first patients in REVERT Liver Cancer trial
23 Jun 2023 //
CLINICAL TRIALS ARENA
The China NMPA Approves TYVYT® in Combination with Bevacizumab
09 May 2023 //
PR NEWSWIRE
Taiho Oncology & Servier Announce in New Engl& Journal pH 3 Data for (LONSURF®)
03 May 2023 //
BUSINESSWIRE
Biocon Biologics facility gets EU GMP certification for Bevacizumab
29 Apr 2023 //
HEALTH ET
Enforcement Report - Week of April 19, 2023
19 Apr 2023 //
FDA
Celltrion Healthcare`s Vegzelma (bevacizumab) Receives Approval in Europe
22 Mar 2023 //
EMA
USFDA issues CRL for Bevacizumab license application moved by Viatris: Biocon
12 Feb 2023 //
ECONOMIC TIMES
Roche`s Tecentriq, Avastin combo cuts risk of liver cancer returning
20 Jan 2023 //
BIOPHARMADIVE
Servier & Taiho Present Survival Data for LONSURF With Bevacizumab at 2023 ASCO
17 Jan 2023 //
BUSINESSWIRE
Bexion doses first participant in trial of colorectal carcinoma therapy
11 Jan 2023 //
CLINICALTRIALSARENA
Outlook Therapeutics® Announces Validation of MAA by theEMA for ONS-5010
22 Dec 2022 //
PRESS RELEASE
Adagene to Collaborate to Evaluate Anti-CTLA-4 SAFEbody ADG126 with Roche
16 Dec 2022 //
GLOBENEWSWIRE
Enterome completes patient enrollment of Phase 2 ROSALIE study evaluating EO2401
12 Dec 2022 //
PRNEWSWIRE
Replimune Enters into Clinical Collaboration Agreement with Roche
07 Dec 2022 //
GLOBENEWSWIRE
Brand Institute Partners on Brand Name Dev for Approved Biologic Medication
19 Oct 2022 //
PRNEWSWIRE
Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01
17 Oct 2022 //
PRNEWSWIRE
Amneal Launches First Biosimilar with ALYMSYS in the United States
03 Oct 2022 //
BUSINESSWIRE
Celltrion USA Receives U.S. FDA Approval for its Oncology Biosimilar Vegzelma
28 Sep 2022 //
BUSINESSWIRE
Celltrion`s Biologic Vegzelma (Bevacizumab) Receives Approval in the U.S.
27 Sep 2022 //
FDA
LYNPARZA Approved in China as Treatment With Bevacizumab for HRD
22 Sep 2022 //
BUSINESSWIRE
